MedTrace Logo

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

NCT00219726 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-08-29

No results posted yet for this study

Summary

The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase who are in relapse after stem cell transplantation.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Imatinib mesylate

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Poitiers University Hospital

    lead OTHER

Principal Investigators

  • François GUILHOT, MD · Department of Oncology Hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE

  • Agnès DEVERGIE, MD · University Hospital "Saint-Louis" - Department of Hematology and Oncology - 75475 PARIS Cedex 10 (FRANCE)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Completion
2007-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219726 on ClinicalTrials.gov